Vasculitis & polymyalgia rheumatica
Infliximab vs interferon-α in the treatment of Behçet’s syndrome: clinical data from the BIO-BEHÇET’S randomized controlled trial
Authors' conclusion
In this first reported, high-quality, head-to-head trial of two biologics in Behçet's, both infliximab and IFN-α2a showed comparable short-term clinical efficacy and safety in refractory active disease of all subtypes.
Study context
- Population
- Patients with active refractory Behçet's syndrome of all subtypes, four UK centres
- Participants
- 79 patients
- Comparison
- Infliximab vs IFN-α2a
- Primary endpoint
- Behçet's Disease Activity Index (BDAI)
- Follow-up
- 12 weeks
Methodological detailsBayesian-designed, pragmatic, standard of care, two-arm, parallel, head-to-head, four UK centres
- Bayesian-designed
- Pragmatic
- Standard of care
- Two-arm
- Parallel
- Head-to-head
- Four UK centres
Primary result
As reported in the abstract
BDAI
- Both treatments were equally effective
Secondary outcomes
Complete cessation of steroids · modest steroid-sparing effect
Secondary outcomes (Behçet's Disease Activity Index (BDAI) at 24 wk, organ-system improvement, QoL, disease activity, steroid use)
- No significant differences; clinically significant within-group reductions over time
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Infliximab vs interferon-α in the treatment of Behçet’s syndrome: clinical data from the BIO-BEHÇET’S randomized controlled trial. Rheumatology (Oxford). Published 21 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →